|Got it thanks!||Viewmont||01/09/23 8:00 PM|
|Hi, I haven't been following AIKI for a||Viewmont||01/09/23 7:40 PM|
|More insider shares purchased today…||db101||12/16/22 5:54 PM|
|More insider shares purchased…||db101||12/15/22 7:17 PM|
|AIKI looks to be headed back to 7…||db101||12/13/22 6:22 PM|
|More insider shares purchased…||db101||12/13/22 3:01 PM|
|A positive week… up 3.11%||db101||12/10/22 6:11 AM|
|…more shares purchased by the CEO||db101||12/08/22 4:58 PM|
|…AIKI seems to be getting its legs||db101||12/07/22 2:41 PM|
|AIKI is undervalued…||db101||11/27/22 1:17 AM|
|AIKI is ready…||db101||11/13/22 3:27 AM|
|The Company reported that on October 5, 2022,||db101||10/06/22 1:31 PM|
|The Company reported that on October 4, 2022,||db101||10/05/22 1:31 PM|
|AIKI is buying more shares… 45k||db101||10/04/22 1:14 PM|
|Shalom Auerbach board member on AMRR doesn’t mess||The-REAL-KING-of-pennies||06/08/22 2:22 PM|
|https://www.prnewswire.com/news-releases/aikido-pharma-secures-interest-in-elect||PStockPickz||03/24/22 7:03 AM|
|Averaging in some .48s||PStockPickz||03/24/22 7:03 AM|
|Snagging some 50s||PStockPickz||03/24/22 6:55 AM|
|AIkido Pharma announces $3M share repurchase program||RNsidersbuying||01/24/22 5:27 PM|
|Classic dog pile here. I'm out and won't||urge2surge||01/22/22 2:06 PM|
|AIKI .47 - So, outsiders have sold this||RNsidersbuying||01/22/22 12:59 PM|
|One of the worst companies I've invested in.||urge2surge||01/15/22 2:43 PM|
|AIKI...72...:partying_face:||georgie18||12/08/21 2:31 PM|
|Get ready for the buttered popcorn...||db101||11/23/21 11:26 AM|
|AIKI...73...Bullish 3 Gap Downs Reversal Pattern to the||georgie18||11/23/21 5:43 AM|
|Looks like good news AlKl||White Lightning||11/12/21 1:32 PM|
|AIkido owns 525,000 shares of DatChat, which it||TheFinalCD||10/12/21 7:15 PM|
|AIKI...92...on the P/M Gappa...:partying_face:||georgie18||10/11/21 8:08 AM|
|Impressed with the CEO management taking investment stakes||urge2surge||09/29/21 9:10 PM|
|Interesting, low ss here...||TGOO||09/29/21 12:42 PM|
|Very volatile but looks ready||Sirpeter||09/29/21 12:27 PM|
|Added let’s see what this can do||sportd||09/29/21 11:35 AM|
|Kaboom!||Sirpeter||09/29/21 11:33 AM|
|Bullish||Sirpeter||09/29/21 11:28 AM|
|Would be nice... it has been ages since||antman||09/16/21 10:57 PM|
|AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching||db101||09/14/21 11:20 AM|
|News...||db101||09/14/21 9:46 AM|
|AIKI...86...Tue, July 27, 2021, 10:00 AM||georgie18||07/27/21 10:11 AM|
|AIKI...97...Bounce off the .85 range on the Bullish||georgie18||07/22/21 6:39 AM|
|$1.10 nice||wesley_||06/23/21 10:07 AM|
|No respect from the street on this company.||urge2surge||06/17/21 8:48 AM|
|Yeah definitely under substantial book value here. Not||urge2surge||06/05/21 9:03 AM|
|BULLISH RESEARCH ARTICLE! Trading under cash and great||Chess Master||06/04/21 12:49 PM|
|* * $AIKI Video Chart 04-21-2021 * *||ClayTrader||04/21/21 5:12 PM|
|AIKI...86...NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido||georgie18||04/16/21 10:17 AM|
|AIKI...$1.20...in the P/M...NEW YORK, April 7, 2021 /PRNewswire/||georgie18||04/07/21 9:25 AM|
|AIKI...$1.17...Bidding the Lower Band to the 20ma to||georgie18||04/03/21 9:27 AM|
|AIKI...$1.17...in the P/M...https://www.otcmarkets.com/stock/AIKI/news/story?e&i||georgie18||03/29/21 9:25 AM|
|$aiki $1.17 ? 0.0 (0.00%)||Taurus69||03/28/21 2:57 PM|
|* * $AIKI Video Chart 03-24-2021 * *||ClayTrader||03/24/21 5:49 PM|
Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms
Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer
Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation
The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia
Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer
Short-term Toxicity Study of DHA-dFdC
Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside
AIkido Pharma Inc. seeks to enhance shareholder value not only through exceptional business performance and practices,
but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual
and institutional investor includes stock price and history, upcoming events and presentations and financial documents.
AIkido Pharma Inc. is traded on the Nasdaq under the ticker symbol AIKI.
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.
The Spherix platform contains patented technology from leading universities and researchers and we seek to develop
our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.
Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.
The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care.
In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.
$AIKI Spherix Incorporated, a biotechnology company,focuses on developing small-molecule anti-cancer therapeutics.
Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
The company's platform consists of patented technology from leading universities and researchers and in the process of developing an
innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at
Austin and Wake Forest University.
It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing pancreatic cancer.
Spherix Incorporated was founded in 1967 and is based in New York, New York.